title: Progression-free survival in bevacizumab-based first-line treatment for patients with metastatic colorectal cancer: is it a really good end point?
authors.forename: Francesco
authors.initials: F
authors.lastname: Montagnani
authors.forename: Cristina
authors.initials: C
authors.lastname: Migali
authors.forename: Giammaria
authors.initials: G
authors.lastname: Fiorentini
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic / Q000379:methods; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D018572:Disease-Free Survival; D023381:Endpoint Determination; D006801:Humans; D009362:Neoplasm Metastasis; D012044:Regression Analysis; D012107:Research Design; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab